{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:15:55Z","timestamp":1792808155588,"version":"4.5.0"},"reference-count":69,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hormone receptor\u2013positive, human epidermal growth factor 2 (HER2)\u2013negative metastatic breast cancer (MBC) represents the most common subtype of MBC and has undergone substantial therapeutic evolution. Treatment has shifted from sequential endocrine therapy (ET) and chemotherapy toward personalized strategies incorporating molecularly targeted agents and antibody-drug conjugates (ADCs), with increasing emphasis on quality of life and shared decision making. CDK4\/6 inhibitors plus ET remain a first-line standard of care in high-resource settings, demonstrating consistently improved progression-free survival (PFS) and, for select agents, overall survival (OS). Management in special populations requires additional consideration of trial and real-world data, toxicity profiles, and patient preferences. Beyond ET, ADCs are reshaping the landscape. Trastuzumab deruxtecan expanded therapeutic utility across HER2-low and HER2-ultralow disease, whereas sacituzumab govitecan and datopotamab deruxtecan provide later-line options. As ADCs emerge as earlier therapies, questions regarding sequencing, cross-resistance, and toxicity remain central to clinical decision making. Metastasis-directed therapy (MDT) in oligometastatic and oligoprogressive breast cancer also requires nuanced decision making. Despite high local control rates with stereotactic body radiotherapy, randomized trials have not demonstrated consistent improvements in PFS or OS in unselected populations. Current evidence supports systemic therapy as the foundation of management, with MDT selectively considered for oligoprogression, symptom prevention, or within clinical trials. Ultimately, management of hormone receptor\u2013positive\/HER2-negative MBC requires dynamic integration of tumor biology, systemic therapy advances, and patient-defined goals of care. As therapeutic complexity increases, shared decision making and equitable access to evidence-based and supportive care services remain essential for delivering high-quality, individualized oncology care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-520518","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:59:09Z","timestamp":1779220749000},"source":"Crossref","is-referenced-by-count":1,"title":["Evolving Treatment Paradigms in Hormone Receptor\u2013Positive, Human Epidermal Growth Factor 2\u2013Negative Metastatic Breast Cancer"],"prefix":"10.1200","volume":"46","author":[{"given":"Sara","family":"Soliman","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zitter","sequence":"additional","affiliation":[{"name":"University of Chicago Department of Radiation and Cellular Oncology, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Walker","sequence":"additional","affiliation":[{"name":"Metastatic Breast Cancer Alliance, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chmura","sequence":"additional","affiliation":[{"name":"University of Chicago Department of Radiation and Cellular Oncology, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Eniu","sequence":"additional","affiliation":[{"name":"Genolier Cancer Center, Genolier, Switzerland"},{"name":"European School of Oncology, Bellinzona, CH, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-1722","authenticated-orcid":true,"given":"Stephanie L.","family":"Graff","sequence":"additional","affiliation":[{"name":"Legorreta Cancer Center at Brown University, Brown University Health Cancer Institute, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.013"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2000"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103069"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"e0336767","DOI":"10.1371\/journal.pone.0336767","article-title":"Safety assessment of cyclin-dependent kinase 4\/6 inhibitors and comparison of time to adverse events","volume":"20","author":"Zhang S","year":"2025","unstructured":"Zhang S, Zhang R, Xia Y, et al: Safety assessment of cyclin-dependent kinase 4\/6 inhibitors and comparison of time to adverse events. PLoS One 20:e0336767, 2025","journal-title":"PLoS One"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53151-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1673284"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01392"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA1000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08035-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03935-w"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00144"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2261"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115225"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105896"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01415-9"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1600892"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00638"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1041"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00676-9"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001294"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410858"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02392"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_2_34_2","article-title":"PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice","volume":"42","author":"Kim E","year":"2024","unstructured":"Kim E, Dhillon PK, Lambert P, et al: PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice. J Clin Oncol 42, 2024 (suppl 16; abstr e13059)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00663"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0728"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02086"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.annonc.2025.09.026","article-title":"Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial","volume":"36","author":"Mayer E","year":"2025","unstructured":"Mayer E, Tolaney SM, Martin M, et al: Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial. Ann Oncol 36:S1-S60, 2025 (suppl 2)","journal-title":"Ann Oncol"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","unstructured":"Hurvitz SA Layman RM Curigliano G et al: VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone Receptor-Positive\/HER2-\/PIK3CA wild-type advanced breast cancer. J Clin Oncol 10.1200\/JCO-25-02643 [epub ahead of print on March 9 2026]","DOI":"10.1200\/JCO-25-02643"},{"key":"e_1_3_2_42_2","unstructured":"National Cancer Institute. Resistance definitions developed from the NCI Breast Cancer Steering Committee (BCSC) Clinical Trials Planning Meeting (CTPM): Next generation trials for estrogen receptor (ER)\u2013positive breast cancer. 2012. https:\/\/www.cancer.gov\/about-nci\/organization\/ccct\/steering-committees\/nctn\/breast-cancer\/resistance-definitions-bcsc-ctpm.pdf"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00228"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq029"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70589-8"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.08.036"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00655-9"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0687"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1007"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.10.030"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01857-3"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00031"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00753"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P2-01-21"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03981-4"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-GS1-09"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","unstructured":"Pistilli B Jhaveri K Im SA et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol 10.1016\/j.annonc.2025.12.017 [epub ahead of print on December 23 2025]","DOI":"10.1016\/j.annonc.2025.12.017"},{"key":"e_1_3_2_62_2","article-title":"Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic enterprise experience, updated","volume":"43","author":"Hoppenworth JE","year":"2024","unstructured":"Hoppenworth JE: Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic enterprise experience, updated. J Clin Oncol 43, 2024 (suppl 16; abstr 1089)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00480"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1117"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac184"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","unstructured":"Mai N Klar Lieberman MM Ferraro E et al: Sequential antibody-drug conjugate therapy in patients with metastatic breast cancer treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO Precis Oncol 10.1200\/PO-24-00898","DOI":"10.1200\/PO-24-00898"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02766-9"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2771"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2025.2545364"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473450"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-520518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:59:20Z","timestamp":1779220760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-520518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-520518"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-520518","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e520518"}}